1-13 of 13
Pamela L. Clemens
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Melody Luo, PhD, Dolly A. Parasrampuria, PhD, Saad Z. Usmani, MD, Maria-Victoria Mateos, Hareth Nahi, MD PhD, Christoph Heuck, Ming Qi, MD PhD, Steven Sun, Pamela L. Clemens, PhD, Honghui Zhou, Yu-Nien (Tom) Sun, PhD, Steven Xu, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3151.
https://doi.org/10.1182/blood-2019-123405
Published: 2019
Journal Articles

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Clinical Trials & Observations
Saad Z. Usmani, Hareth Nahi, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Ajai Chari, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Kevin Liu, Jesus San-Miguel
Journal: Blood
Blood (2019) 134 (8): 668–677.
https://doi.org/10.1182/blood.2019000667
Published: 2019
Includes: Supplemental data
Journal Articles

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Clinical Trials & Observations
Ajai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, Joan Bladé, Lotfi Benboubker, Albert Oriol, Bertrand Arnulf, Paula Rodriguez-Otero, Luis Pineiro, Andrzej Jakubowiak, Carla de Boer, Jianping Wang, Pamela L. Clemens, Jon Ukropec, Jordan Schecter, Sagar Lonial, Philippe Moreau
Journal: Blood
Blood (2019) 134 (5): 421–431.
https://doi.org/10.1182/blood.2019000722
Published: 2019
Journal Articles

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Ola Landgren, MD PhD, Michele Cavo, MD, Ajai Chari, MD, Yael C Cohen, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter M. Voorhees, MD, Jane Estell, FRACP, Irwindeep Sandhu, MDFRCPC, Matthew Jenner, Catherine Williams, Niels WCJ van de Donk, MD PhD, Meral Beksac, MD, Hartmut Goldschmidt, MD, Philippe Moreau, Steven Kuppens, Rajesh Bandekar, Tobias Neff, Annelore Cortoos, MD, Pamela L Clemens, PhD, Ming Qi, Homer Adams, III, PhD, Craig C Hofmeister, MDMPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 1994.
https://doi.org/10.1182/blood-2018-99-113467
Published: 2018
Journal Articles

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Ajai Chari, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Hareth Nahi, MD PhD, Jie Tang, Peter Hellemans, Brenda Tromp, MSc, Pamela L Clemens, PhD, Andrew Farnsworth, Jesus F San-Miguel, MD PhD, Saad Z. Usmani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1995.
https://doi.org/10.1182/blood-2018-99-113590
Published: 2018
Journal Articles

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pamela L Clemens, PhD, Steven Xu, PhD, Melody Luo, PhD, Ajai Chari, MD, Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Jesus F San-Miguel, MD PhD, X. Yu-Nien Sun, Andrew Farnsworth, Tara Masterson, Peter Hellemans, Ming Qi, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2006.
https://doi.org/10.1182/blood-2018-99-113161
Published: 2018
Journal Articles

Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses

Xu Steven Xu, Philippe Moreau, Saad Z. Usmani, MD, Sagar Lonial, MD, Andrzej Jakubowiak, MD PhD, Albert Oriol, MD, Amrita Krishnan, MD, Joan Bladé, MD PhD, Melody Luo, PhD, Yu-Nien Sun, PhD, Liping Zhang, William Deraedt, Ming Qi, MD PhD, Jon Ukropec, PhD, Pamela L Clemens, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1970.
https://doi.org/10.1182/blood-2018-99-113171
Published: 2018
Journal Articles

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Ajai Chari, Hareth Nahi, Maria-Victoria Mateos, MD, Henk M. Lokhorst, Jonathan L. Kaufman, MD, Philippe Moreau, MDPhD, Albert Oriol, MD, Torben Plesner, MD, Lotfi Benboubker, MD, Peter Hellemans, Tara Masterson, Pamela L Clemens, Kevin Liu, Jesus F. San-Miguel, MD, Saad Z Usmani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 838.
https://doi.org/10.1182/blood.V130.Suppl_1.838.838
Published: 2017
Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1149.
https://doi.org/10.1182/blood.V128.22.1149.1149
Published: 2016
Journal Articles

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

X. Steven Xu, Sam Liao, PhD, Meletios A Dimopoulos, Pieter Sonneveld, MD PhD, P. Joy Ho, Andrew Belch, MD, Merav Leiba, MD, Marcelo Capra, MD PhD, David Gomez, MD, Eva Medvedova, MD, Shinsuke Iida, MD PhD, Chang-Ki Min, MD, Ming Qi, Jordan Schecter, Nushmia Z. Khokhar, Xiaoyu Yan, Liping Zhang, Pamela L. Clemens
Journal: Blood
Blood (2016) 128 (22): 3340.
https://doi.org/10.1182/blood.V128.22.3340.3340
Published: 2016
Journal Articles

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Clinical Trials & Observations
Torben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A. Kate Sasser, Mary E. Guckert, Carla de Boer, Nushmia Z. Khokhar, Howard Yeh, Pamela L. Clemens, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson
Journal: Blood
Blood (2016) 128 (14): 1821–1828.
https://doi.org/10.1182/blood-2016-07-726729
Published: 2016
Includes: Supplemental data
Journal Articles

Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

Xu Steven Xu, Xiaoyu Yan, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Peter M. Voorhees, MD, Kevin Liu, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Juan Jose Perez Ruixo, Honghui Zhou, Pamela L Clemens
Journal: Blood
Blood (2015) 126 (23): 4254.
https://doi.org/10.1182/blood.V126.23.4254.4254
Published: 2015
Journal Articles

Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Xiaoyu Yan, Pamela L Clemens, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Robert Z. Orlowski, MD PhD, Nedjad Losic, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Kristen Lantz, Juan Jose Perez Ruixo, Honghui Zhou, Xu Steven Xu
Journal: Blood
Blood (2015) 126 (23): 4222.
https://doi.org/10.1182/blood.V126.23.4222.4222
Published: 2015